Ozempic® (semaglutide) is an injectable glucagon-like peptide-1 (GLP-1) receptor agonist. It is approved to improve blood sugar control in adults with type 2 diabetes, to reduce cardiovascular risk in people with type 2 diabetes and established heart disease, and, since January 2025, to slow kidney decline in people with type 2 diabetes and chronic kidney disease. It is also now available as a tablet as well as an injection.
Joint pain is one of the side effects patients ask about most often, and it is one of the most commonly searched questions about the medication. The honest answer has changed since this article was first published. Joint pain is not a listed adverse reaction of semaglutide, several 2026 analyses have found no increase in joint problems compared with placebo, and a large randomized trial found that semaglutide substantially reduced knee osteoarthritis pain. That does not mean nobody aches on treatment. It means the explanation is usually something else, and knowing which explanation applies is what leads to the right fix, whether that is protein and resistance training during rapid weight loss and muscle loss, hydration, or treating a gout flare.
⚠ Correction, September 2026: An earlier version of this article stated that Novo Nordisk reported joint pain in about 1% of clinical trial participants. That figure does not appear in the manufacturer’s safety information or in the FDA prescribing information, and it has been removed. The current evidence is set out below, with sources.
Not as a recognized side effect. Joint pain does not appear in the adverse reactions section of the current prescribing information for semaglutide, and the randomized trial evidence has not shown more joint problems in people taking it than in people taking placebo.
Patients do nonetheless report sore, stiff or aching joints while taking it, and those reports are real. What has changed is the explanation. Rather than the medication acting directly on joint tissue, the causes that fit the evidence relate to what happens around a GLP-1 medication: rapid weight loss, changes in uric acid, loss of muscle that normally supports a joint, dehydration during dose escalation, and conditions that were already developing and become noticeable once someone is paying closer attention to their body.
The practical consequence is that joint pain on Ozempic® is worth investigating rather than accepting. In most cases there is something specific to identify and treat.
No. Here is what the current labels actually list at a rate of 5% or more, alongside the search term that brings most people to this page.
| Reported in clinical trials | Ozempic® 0.5 mg | Ozempic® 1 mg | Wegovy® 2.4 mg |
|---|---|---|---|
| Nausea | 15.8% | 20.3% | 44% |
| Diarrhea | 8.5% | 8.8% | 30% |
| Vomiting | 5.0% | 9.2% | 24% |
| Constipation | 5.0% | 3.1% | 24% |
| Abdominal pain | 7.3% | 5.7% | 20% |
| Joint pain (arthralgia) | Not listed | Not listed | Not listed |
Source: FDA prescribing information for Ozempic® (revised October 2025) and Wegovy® (revised February 2026). Arthralgia appears in neither the clinical trial tables nor the postmarketing sections of either label.
Because joint pain is not a labeled adverse reaction, there is no characteristic pattern of drug-related joint pain to describe. What can be described is what people actually report to safety databases.
A 2026 analysis of 15,052 musculoskeletal reports in the FDA Adverse Event Reporting System found no signal for musculoskeletal problems as a whole with incretin-based medications. At the level of individual events, the signals associated with GLP-1 medications were back pain and muscle pain (myalgia); for tirzepatide, the drug in Mounjaro® and Zepbound®, it was muscle atrophy. Median time to onset was 30 days or less, which points to the early titration period rather than long-term use.
That distinction matters in practice. Much of what patients describe as joint pain on a GLP-1 is muscle or soft-tissue pain around the joint, and the two respond to very different things.
When a patient reports new joint pain on Ozempic®, these are the explanations that fit the published evidence.
| Explanation | What is behind it | What it typically looks like |
|---|---|---|
| Gout during rapid weight loss | GLP-1 medications lower uric acid overall, largely through weight loss, but rapid weight reduction can raise it temporarily — a pattern well documented after bariatric surgery | Sudden, severe pain in one joint, often the big toe, ankle or knee, in the early weeks. Red, hot and hard to bear weight on |
| Muscle loss and deconditioning | A meaningful share of weight lost without resistance training is lean mass, and weaker muscle means less support around the joint | Aching around the joint rather than inside it, usually knees and hips, worse after activity |
| Muscle pain described as joint pain | The documented reporting signals for GLP-1 medications are back pain and myalgia, typically within the first 30 days | Diffuse aching, both sides of the body, no swelling, often alongside fatigue in the first weeks |
| Dehydration from gastrointestinal side effects | Vomiting and diarrhea during dose escalation, combined with reduced fluid intake as appetite falls | Generalized aches and leg cramps that improve with rehydration |
| An arthritis that was already developing | Obesity is itself a risk factor for rheumatoid arthritis. A 2026 case-control study of 4,535 people with rheumatoid arthritis and 22,675 matched controls found short-term GLP-1 exposure associated with new-onset disease, with the association fading in people treated longer — a pattern more consistent with earlier detection than with a drug effect | Morning stiffness lasting more than 30 minutes, symmetrical small joints, visible swelling. This one is referred, not reassured |
None of these mechanisms describe semaglutide damaging joint tissue. Each of them is addressable, and most do not require stopping treatment.
Anyone can experience aches during treatment, but the people most likely to are those in whom the mechanisms above apply:
The risk factors listed in older consumer articles — blood thinners, immunosuppressants, corticosteroids — are not supported by the semaglutide evidence and have been removed from this guide.
There is no labeled incidence figure, because joint pain is not a labeled adverse reaction. The best available evidence comes from pooled trial data.
A systematic review and meta-analysis of 43 randomized controlled trials including 100,488 participants, published in February 2026, examined musculoskeletal events reported during GLP-1 treatment. It found no significant difference between GLP-1 users and control groups for gouty arthritis, rheumatoid arthritis, osteoarthritis, osteoporotic fracture, synovitis or intervertebral disc protrusion.
In other words: across 100,000 trial participants, joint problems did not occur more often on these medications than on placebo.
This is where the evidence has moved furthest. STEP 9, published in the New England Journal of Medicine in October 2024, was a 68-week randomized, double-blind, placebo-controlled trial at 61 sites in 11 countries. It enrolled 407 adults with obesity and moderate knee osteoarthritis with at least moderate pain (average age 56, average BMI 40.3).
STEP 9: improvement at 68 weeks
WOMAC pain score (0–100, lower is better) started at an average of 70.9. SF-36 physical function score, higher is better. All differences P<0.001. Bars are scaled for comparison.
A second line of evidence arrived in June 2026. A retrospective analysis of the TriNetX research network followed adults diagnosed with knee osteoarthritis and compared GLP-1 users with matched non-users, in groups ranging from 13,351 to 42,062 patients. One year of any GLP-1 medication was associated with a 2.80 percentage point lower cumulative risk of knee replacement at eight years (hazard ratio 0.90). Three years of semaglutide or tirzepatide was associated with a 4.71 percentage point lower risk (hazard ratio 0.72). The authors are explicit that this is an observed association rather than proof of cause, and that prospective trials are needed.
Separating these is the single most useful thing a patient can do before their appointment, because the evidence points toward muscle rather than joint involvement.
| Joint pain | Muscle pain | Cramps | |
|---|---|---|---|
| Where it is felt | Inside a specific joint | In the soft tissue around or between joints | In a muscle belly, often calf or foot |
| What makes it worse | Moving or loading that joint | Activity generally; often sore to touch | Comes on suddenly, often at night |
| Swelling or heat | Possible, and important if present | No | No |
| Usual pattern | One or a few joints | Diffuse, both sides | Episodic, seconds to minutes |
| First thing to address | Assessment, especially if swollen | Protein intake and resistance training | Hydration and electrolytes |
Rapid weight loss of any kind can reduce bone mineral density, which is one reason resistance training matters during treatment. The specific evidence for semaglutide is reassuring so far. An analysis presented at ENDO 2026 compared 26,324 people taking semaglutide with 33,555 taking other weight-management medications and reported roughly 15% fewer fractures in the semaglutide group. That research was presented as a conference abstract and has not yet been peer reviewed, so it should be read as encouraging rather than settled.
The picture is broadly the same across the class. Arthralgia is not a listed adverse reaction for tirzepatide, the active ingredient in Mounjaro® and Zepbound®, any more than it is for semaglutide, and tirzepatide was included in the knee replacement analysis above.
There is one difference worth knowing. In the same FDA reporting analysis, the musculoskeletal signal for tirzepatide was muscle atrophy rather than back pain, which is consistent with the greater average weight loss achieved with it and the lean mass that comes with that loss. If you are comparing agents, IAPAM’s guides to tirzepatide dosing and Zepbound® versus Ozempic® cover the differences in detail, and the investigational triple agonist retatrutide is covered separately.
The most common side effects of Ozempic® are gastrointestinal: nausea, diarrhea, vomiting, abdominal pain and constipation, with rates shown in the table above. Decreased appetite is expected rather than adverse. Less common but more serious risks include pancreatitis, gallbladder disease, acute kidney injury from dehydration, and a boxed warning regarding thyroid C-cell tumors observed in rodents.
On vision: in June 2025 the European Medicines Agency concluded that non-arteritic anterior ischemic optic neuropathy (NAION), a rare condition affecting the optic nerve, is a very rare side effect of semaglutide medicines, affecting up to 1 in 10,000 people, and required the product information in Europe to say so. Sudden vision loss or rapidly worsening eyesight during treatment should be assessed urgently. IAPAM’s article on Ozempic®, Wegovy® and vision loss covers what is and is not established.
Management depends on which of the five explanations applies, which is why the assessment matters more than the pain reliever.
Never stop or change a dose without speaking to the prescribing clinician first. Most of the causes above can be managed while treatment continues, and stopping unnecessarily gives up the metabolic benefit — and, in people with knee osteoarthritis, the pain improvement that the weight loss itself produces.
There is no way to prevent a side effect that is not established. There are three things that consistently reduce the aches patients do report:
Adequate hydration, a balanced diet and low-impact movement round it out. A pre-treatment conversation about existing joint problems and any history of gout also makes it much easier to interpret symptoms if they appear later.
Musculoskeletal complaints reported with GLP-1 medications typically begin within the first 30 days of starting treatment or increasing a dose, which is itself a useful clue. Aches related to dehydration or a rapid dose increase often settle within days to a few weeks once the cause is addressed. A gout flare follows its own course and needs treatment.
Pain that persists, involves a swollen joint, or continues after the medication is stopped should be assessed rather than waited out. Persisting symptoms usually indicate a separate diagnosis that deserves its own management. The same applies to symptoms that appear when treatment ends, which is covered in more detail in what happens when you stop taking Ozempic®.
Persistent joint pain limits mobility, disrupts sleep and daily activity, and can lead people to stop a medication that is managing their diabetes or weight. That last consequence is the most costly one, because it is usually avoidable.
It is worth holding the trial evidence alongside the complaint: in STEP 9, physical function improved substantially more on semaglutide than on placebo. For most patients with painful knees and obesity, treatment moved function in the right direction. When an individual patient’s experience runs the other way, that is a signal to investigate, not a reason to assume the medication is doing damage.
A short, structured assessment settles most of these presentations in a single visit:
These are the same clinical judgments that underpin safe GLP-1 prescribing generally: patient selection, titration, side-effect management and monitoring. You can sample IAPAM’s clinical GLP-1 training with the free 1-CME module below.
Get self-paced access to a real IAPAM provider module covering GLP-1 and GIP receptor agonists, clinical protocols, and patient safety, and claim 1 AMA PRA Category 1 CME™ when you finish. It’s a free sample of our Certified Medical Weight Management Provider™ (CWMP™) program.
What’s Inside Your Free Module
Eligibility: MD/DO, NP, PA, RN
Enter your details and we’ll email your access link.
Joint pain is not a listed side effect of Ozempic®. It does not appear in the FDA prescribing information for Ozempic® or Wegovy®, and randomized trials have not found more joint problems on semaglutide than on placebo. Some patients do report aching joints during treatment, but the cause is usually something other than the medication acting on the joint itself, such as a gout flare during rapid weight loss, muscle loss, or dehydration from gastrointestinal side effects.
No. Arthralgia, the medical term for joint pain, does not appear in the adverse reactions tables or the postmarketing section of the current Ozempic® prescribing information, revised October 2025, or the Wegovy® prescribing information, revised February 2026. The side effects listed at 5% or more are nausea, vomiting, diarrhea, abdominal pain and constipation.
In the STEP 9 trial published in the New England Journal of Medicine in October 2024, adults with obesity and moderate knee osteoarthritis who took semaglutide 2.4 mg for 68 weeks improved their WOMAC knee pain score by 41.7 points compared with 27.5 points on placebo, and lost 13.7% of body weight compared with 3.2%. Physical function also improved more on semaglutide.
Musculoskeletal complaints reported with GLP-1 medications usually begin within the first 30 days of starting or increasing a dose, and aches related to dehydration or a rapid dose increase often settle within days to a few weeks. Pain that persists, involves a swollen joint, or continues after stopping the medication should be assessed rather than waited out, because it is more likely to have a separate cause.
The distinction matters because the reporting signals for GLP-1 medications are back pain and muscle pain rather than joint pain. Joint pain is usually felt in a specific joint, is worse when that joint moves, and may come with swelling, heat or stiffness. Muscle pain is felt in the soft tissue around the joint, is more diffuse, often affects both sides, and typically has no swelling.
Arthralgia is not listed as an adverse reaction for tirzepatide, the active ingredient in Mounjaro® and Zepbound®, any more than it is for semaglutide. In pharmacovigilance data, the musculoskeletal reporting signal associated with tirzepatide is muscle atrophy rather than joint pain, which is consistent with lean mass loss during rapid weight reduction. The same knee osteoarthritis benefit seen with semaglutide has also been observed in real-world analyses that included tirzepatide.
Do not stop or change the dose without speaking to the prescribing clinician. Most joint aches during treatment have an identifiable cause that can be addressed without stopping, such as increasing protein intake and resistance training, correcting dehydration, slowing the dose increase, or treating a gout flare. A single hot swollen joint, or symmetrical small joint pain with prolonged morning stiffness, should be assessed promptly because it suggests a separate diagnosis.
Joint pain is not an established side effect of Ozempic®, and the weight of recent evidence points the other way: across 43 randomized trials there was no excess of joint problems, and in people with obesity and knee osteoarthritis, semaglutide produced a substantial reduction in knee pain and a meaningful improvement in physical function. Real-world data now associate GLP-1 treatment with a lower long-term risk of knee replacement.
That said, patients who ache on treatment deserve an explanation rather than reassurance. In most cases there is one — a gout flare during rapid loss, lean muscle loss, dehydration, or a joint condition that was already developing — and each has a different answer. Recognizing which is which is a core clinical skill in medical weight management. IAPAM’s GLP-1 certification training for medical weight management providers covers patient selection, titration, side-effect management and monitoring, with up to 6 AMA PRA Category 1 CME credits online.
Explore GLP-1 Certification Training →
Disclaimer: The information provided here is for general knowledge only and should not be considered medical advice. For any questions or concerns about your health or medications, please consult your physician or healthcare provider. They are best equipped to provide guidance specific to your medical needs.
IAPAM Learning Lab
Patients are already asking about GLP-1s, injectables, PRP, lasers, and aesthetic treatments. Build the knowledge to have better clinical conversations now—on a schedule that works around your practice.
Need hands-on BOTOX® training instead? Explore IAPAM’s Botox training options →
Currently, there are no known specific measures to prevent the joint pain caused by Ozempic®, as it largely depends on an individual’s response to the medication.
Nevertheless, adopting certain strategies can help lessen the severity or frequency of joint pain outbreaks. Regular low-impact exercises, maintaining a healthy weight, and a balanced diet can all contribute to overall joint health and may help in reducing the side effects.
Avoiding situations that may exacerbate joint pain can be helpful, such as heavy physical activities or repetitive movements that strain the joints. Consulting with your healthcare provider before beginning Ozempic® may also help identify pre-existing risk factors and potentially create a preventive action plan.
As with any chronic pain, joint pain caused by Ozempic®c can impact a patient’s quality of life significantly. Continuous joint pain can limit a person’s mobility and disrupt daily activities. It can lead to reduced physical fitness due to enforced inactivity and can cause emotional distress, impacting overall wellbeing.
Moreover, the discomfort can disrupt sleep and result in fatigue, which can affect concentration and productivity, thereby adversely impacting social and professional life.
Most importantly, persistent joint pain might dissuade patients from adhering to their prescribed medication regimen, thus negatively affecting their ability to manage their diabetes. An open and frank discussion with healthcare professionals about this impact is the first step towards addressing these issues.
Disclaimer: The information provided here is for general knowledge only and should not be considered medical advice. For any questions or concerns about your health or medications, please consult your physician or healthcare provider. They are best equipped to provide guidance specific to your medical needs.
Medical Weight Management Training
Build the clinical, operational, and business foundations to evaluate GLP-1 weight-management services for your practice—without handing your patient relationships to a corporate intermediary.
Explore GLP-1 Certification Training →Want to add Botox® training to your broader practice plan? Explore IAPAM’s Botox training options →
In order to have a successful aesthetic practice, you need to have effective advertising to attract people to your business.
This includes spending those
While Ozempic® has been proven effective in clinical trials, a potential reason for not losing weight on Ozempic® is related to dietary and lifestyle choices.
Failure to refrigerate the Ozempic® within the correct temperature range may result in reduced effectiveness and potential harm to the user.
Learn about the effects of stopping Ozempic® for diabetes & weight loss. Manage withdrawal & maintain health gains.
Request your Quick Start Checklist for Starting or Integrating a New GLP-1 for Weight Loss Guide.
Terms and conditions apply. Offer expires October 31.